中草药治疗HIV/AIDS患者药物性肝损伤:随机对照试验的系统评价
与常规治疗相比,单用中草药或联合常规治疗可降低AST、ALT、总胆红素和直接胆红素,并提高有效率(低确定性证据)。辅助性T细胞无显著差异,仅1项RCT报告无不良反应,样本量小且质量低。
要点
- 中草药可能改善HIV/AIDS患者药物性肝损伤的肝功能指标和有效率。
- 证据确定性低,样本量小,需要大样本高质量试验验证。
- 对辅助性T细胞无显著影响,安全性数据有限。
核心结论
- 中草药可能改善HIV/AIDS患者药物性肝损伤的肝功能指标和有效率,但证据确定性低。
主要发现
- 与常规治疗相比,单用中草药降低AST(MD=-11.47 U/L,95%CI[-13.05, -9.89],低确定性)。
- 单用中草药降低ALT(MD=-2.68 U/L,95%CI[-4.27, -1.08],低确定性)。
- 单用中草药降低总胆红素(MD=-4.31 mmol/L,95%CI[-5.66, -2.96],低确定性)。
- 单用中草药降低直接胆红素(MD=-3.19 mmol/L,95%CI[-3.87, -2.51],低确定性)。
- 单用中草药提高有效率(RR=1.13,95%CI[1.06, 1.20],低确定性)。
关键数值与推荐
- 中草药联合常规治疗对比常规治疗在上述结局中也显示显著差异。
- 辅助性T细胞在各比较中无显著差异。
- 仅1项RCT报告安全性,试验期间未发现不良反应。
临床怎么用
- 可考虑将中草药作为HIV/AIDS患者药物性肝损伤的辅助治疗,但需告知患者证据确定性低。
- 使用中应监测肝功能和安全性,因安全性数据有限。
局限性
- 样本量小(732例),研究质量低。
- 仅1项RCT报告安全性,安全性证据不足。
- 需要更大样本的高质量试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To explore the effectiveness and safety of Chinese herbal medicine (CHM) for drug-induced liver injury (DILI) in patients with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS). METHODS: A systematic search was made of eight databases (Pubmed, Cochrane Library, Web of Science, Embase, CNKI, Wanfang, VIP, Sinomed) and two trial registries (WHO ICTRP, ClinicalTrials.gov) from inception to September 2022. The effect size was presented as risk ratio (RR) or mean difference (MD) with their 95% confidence interval (CI). The Cochrane Risk of Bias and Grading of Recommendations, Assessment, Development and Evaluations (GRADE) tools were used for quality appraisal. RESULTS: Ten randomized controlled trials (RCTs) involving 732 participants were included. Comparing CHM alone with routine treatment, the CHM group showed lower aspartate aminotransferase (MD=-11.47 U/L, 95%CI[-13.05, -9.89], low certainty), lower alanine aminotransferase (MD=-2.68 U/L, 95%CI[-4.27, -1.08], low certainty), lower total bilirubin (MD=-4.31 mmol/L, 95%CI[-5.66, -2.96], low certainty), lower bilirubin direct (MD=-3.19 mmol/L, 95%CI[-3.87, -2.51], low certainty), and higher effective rate (assessed by symptoms and liver indicators) (RR=1.13, 95%CI[1.06, 1.20], low certainty). A significant difference was also found in CHM plus routine treatment versus routine treatment in the previous outcomes. No significant difference was found on helper T cells among these comparisons. Only one RCT reported safety of CHM and found no adverse reaction during the trial. CONCLUSIONS: CHM may improve the liver function indices and effective rate for HIV/AIDS patients with DILI. However, the sample size was small and quality was low. Larger-samples of high-quality trials are needed.
引用
- Zhang XW, Li J, Hou WB, et al. Chinese herbal medicine for drug-induced liver injury in patients with HIV/AIDS: A systematic review of randomized controlled trials. Integr Med Res. 2022. PMID: 36632130. doi:10.1016/j.imr.2022.100918
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。